Xencor, Inc.
Clinical trials sponsored by Xencor, Inc., explained in plain language.
Xencor, Inc.
XNCR
NASDAQ
Biotech engineering antibody therapeutics for cancer and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kidney cancer: experimental drug XmAb819 enters human trials Results expected Feb 2027 (estimated)
- First human trial of a new antibody drug begins Results expected May 2027 (estimated)